The hepatitis B vaccine is one of the most potent immunizations, usually providing decades of protection against the deadly liver virus. But in about 10% of people it doesn’t work, and in 2020, Amy Huei-Yi Lee, a systems biologist at Simon Fraser University, and her colleagues set out to determine whether they could predict who would benefit. The scientists found that data on recipients’ immune systems such as the abundance of certain proteins and the activity patterns of a few genes foretold whether they would generate defenses against the virus. “We got a sense of what factors drive the vaccine response and what [doesn’t],” Lee says.
Trending
- Cross River sets 30m-seedling coffee target
- NBSA, Journalists unite to boost blood donations
- Northwest records highest childhood malaria prevalence in Nigeria
- Yobe leads bottom 12 as Bayelsa receives lowest LGA FAAC allocation in September
- Sokoto ranks among states with lowest skilled antenatal care coverage
- CBN appoints 8 agents to monitor Nigeria’s crude oil, gas exports [FULL LIST]
- 20:@20:50:20 – Inside the Dynastic DNA of Sultan Muhammad Sa’ad Abubakar’s Forebears
- NAOWA calls for breast cancer screening, support
